Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

(2000): Rodrigues de Oliveira J+, Gastroenterol Clin Biol
24(5), 592
(2000): Schattner A+, J Intern Med 247(1), 153 (fatal)
(2000): Tejos S+, Rev Med Chil 128(12), 1349
(1999): Romero Gomez M+, Med Clin (Barc) 113(9), 357 (3
cases)
(1999): Romero-Gomez M+, Liver 19(2), 164
(1999): Weiss P, Isr Med Assoc J 1(3), 221
(1999): Weiss P+, Isr Med Assoc J 1(2), 89
(1998): Van Steenbergen W+, JHepatol29(1), 135 (6 cases)
Nephrotoxicity
(2004): Benini D+, Pediatr Nephrol 19(2), 232
(2004): Magnani C+, Eur J Obstet Gynecol Reprod Biol
116(2), 244
(2002): Van der Niepen P+,, NephrolDialTransplant17(2), 315
(2000): Balasubramaniam J, Lancet 355(9203), 575
(1997): Apostolou T+, NephrolDialTransplant12(7), 1493
*Note: Sulfamethoxazole is a sulfonamide and can be absorbed
systemically. Sulfonamides can produce severe, possibly fatal,
reactions such as toxic epidermal necrolysis and Stevens–Johnson
syndrome
NIMODIPINE
Trade names: Admon; Nimotop (Bayer); Periplum; Vasotop
Indications: Subarachnoid hemorrhage
Category: Calcium channel blocker
Half-life: 3 hours
Clinically important, potentially hazardous interactions
with: epirubicin, imatinib
Reactions
Skin
Acne (